Literature DB >> 16406147

DNA prime/protein boost immunization against HIV clade C: safety and immunogenicity in mice.

Robert A Rasmussen1, Helena Ong, Christian Kittel, Claudia R Ruprecht, Flavia Ferrantelli, Shiu-Lok Hu, Patricia Polacino, Patricia Policano, Jennifer McKenna, Jane Moon, Bruce Travis, Ruth M Ruprecht.   

Abstract

The induction of both cellular and humoral immunity is an important goal for vaccine development against HIV. As a step towards the development of an efficacious vaccine against HIV clade C, the world's most prevalent strain, a combination DNA prime/protein boost immunization strategy was tested. A DNA expression vector was prepared encoding a codon-optimized env gene derived from a pediatric HIV clade C isolate, 1084i. Mice were immunized with HIV1084i env-encoding DNA, then boosted with homologous 1084i gp160. HIV1084i Env-specific T-cell responses were induced with DNA vaccination alone, but the strongest cellular immune responses were seen after boosting with gp160. Immunization with gp160 alone induced high-titer antibodies but required two inoculations. In contrast, high-titer antibodies were seen after a single 1084i gp160 boost in DNA-primed animals. All animals given gp160 inoculations, whether DNA primed or not, developed neutralizing antibodies reactive with HIV1084i and a macaque-passaged simian/human immunodeficiency construct, SHIV-1084ip. The results demonstrate the utility of this DNA prime/protein boost approach to generate cellular immunity, as well as neutralizing antibodies, against HIV clade C env antigens.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16406147     DOI: 10.1016/j.vaccine.2005.11.063

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges.

Authors:  Samir K Lakhashe; Vijayakumar Velu; Gaia Sciaranghella; Nagadenahalli B Siddappa; Janet M Dipasquale; Girish Hemashettar; John K Yoon; Robert A Rasmussen; Feng Yang; Sandra J Lee; David C Montefiori; Francis J Novembre; François Villinger; Rama Rao Amara; Maria Kahn; Shiu-Lok Hu; Sufen Li; Zhongxia Li; Fred R Frankel; Marjorie Robert-Guroff; Welkin E Johnson; Judy Lieberman; Ruth M Ruprecht
Journal:  Vaccine       Date:  2011-07-14       Impact factor: 3.641

2.  Bimodal AIDS vaccine approach: induction of cellular as well as humoral immunity can protect from systemic infection.

Authors:  Robert A Rasmussen; Samir K Lakhashe; Ruth M Ruprecht
Journal:  Vaccine       Date:  2010-05-26       Impact factor: 3.641

3.  Generation of recombinant vaccinia viruses via green fluorescent protein selection.

Authors:  Sergei Popov; Saied Mirshahidi; Sosthène Essono; Ruijiang Song; Xiaowei Wang; Ruth M Ruprecht
Journal:  DNA Cell Biol       Date:  2009-03       Impact factor: 3.311

4.  Purification of recombinant vaccinia virus-expressed monomeric HIV-1 gp120 to apparent homogeneity.

Authors:  Wenjin Guo; Brad Cleveland; Thaddeus M Davenport; Kelly K Lee; Shiu-Lok Hu
Journal:  Protein Expr Purif       Date:  2013-05-09       Impact factor: 1.650

5.  Prime immunization with rotavirus VLP 2/6 followed by boosting with an adenovirus expressing VP6 induces protective immunization against rotavirus in mice.

Authors:  Hongli Zhou; Li Guo; Min Wang; Jianguo Qu; Zhendong Zhao; Jianwei Wang; Tao Hung
Journal:  Virol J       Date:  2011-01-05       Impact factor: 4.099

6.  Vaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protection.

Authors:  Samir K Lakhashe; Wendy Wang; Nagadenahalli B Siddappa; Girish Hemashettar; Patricia Polacino; Shiu-Lok Hu; François Villinger; James G Else; Francis J Novembre; John K Yoon; Sandra J Lee; David C Montefiori; Ruth M Ruprecht; Robert A Rasmussen
Journal:  PLoS One       Date:  2011-07-20       Impact factor: 3.240

7.  Overlapping synthetic peptides as vaccines.

Authors:  Shisong Jiang; Ruijiang Song; Sergei Popov; Saied Mirshahidi; Ruth M Ruprecht
Journal:  Vaccine       Date:  2006-06-05       Impact factor: 3.641

8.  Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses.

Authors:  Victor Sanchez-Merino; Eloisa Yuste; Carolina Beltran-Pavez; Ilja Bontjer; Nuria Gonzalez; Maria Pernas; Alberto Merino-Mansilla; Alex Olvera; Jose M Miro; Christian Brander; Jose Alcami; Rogier W Sanders
Journal:  J Virol       Date:  2021-10-20       Impact factor: 5.103

9.  Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission.

Authors:  Jennifer D Watkins; Anton M Sholukh; Muhammad M Mukhtar; Nagadenahalli B Siddappa; Samir K Lakhashe; Mikyung Kim; Ellis L Reinherz; Sandeep Gupta; Donald N Forthal; Quentin J Sattentau; Francois Villinger; Davide Corti; Ruth M Ruprecht
Journal:  AIDS       Date:  2013-06-01       Impact factor: 4.177

10.  Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusing.

Authors:  Michael Humbert; Robert A Rasmussen; Helena Ong; Fabian M P Kaiser; Shiu-Lok Hu; Ruth M Ruprecht
Journal:  PLoS One       Date:  2008-12-15       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.